AI-Native Scoping Reviews & Evidence Mapping

Popliteal artery aneurysm treatment is more than open vs endovascular repair: outcome depends on conduit, approach, runoff, thrombus burden, acuity, and sex-specific risk. The full SAIMSARA evidence map gives humans and AI agents a structured, reference-linked view of 188 original studies and the key treatment signals.

PAES is a high-stakes diagnosis in young exertional claudicants: early recognition and musculotendinous release can preserve long-term patency, while delayed diagnosis may lead to thrombosis, grafting, or failed stenting. The full SAIMSARA evidence map gives humans and AI agents a structured, reference-linked view of 227 original studies, separating anatomical PAES, functional PAES, dynamic diagnostics, surgical outcomes, botulinum toxin evidence, CECS overlap, and unresolved classification gaps.

Iliac artery endofibrosis is a hidden performance-limiting vascular disease of endurance athletes, often missed by resting tests but revealed by post-exercise hemodynamics and dynamic imaging. The full SAIMSARA evidence map gives clinicians, researchers, and LLM agents a structured, reference-linked view of diagnosis, mechanisms, open surgery, endovascular limits, and return-to-sport outcomes — ready for human reading and machine reasoning.

This SAIMSARA review maps 261 original studies comparing AVF and AVG for hemodialysis access, showing where fistulas dominate on durability, infection, mortality, and cost — and where grafts may be clinically preferable for frail, catheter-dependent, or poor-vein patients. The full evidence map gives humans and LLMs a structured, reference-linked view of patency, complications, survival, economics, patient subgroups, and access-selection trade-offs — ready for clinical reading, reasoning, and machine-readable evidence use.

Postoperative complications in vascular surgery are not a single risk — they are a procedure-specific spectrum dominated by cardiac injury, wound/groin infection, renal dysfunction, pulmonary failure, and post-discharge events. This review maps where the danger concentrates and why generic risk calculators are insufficient for modern vascular practice.

TEVAR is no longer just a less invasive alternative to open repair — across type B dissection, traumatic injury, and thoracic aneurysm, it has become a strategy whose success depends on timing, landing-zone judgment, branch preservation, and complication control. This review shows where TEVAR clearly wins, where the evidence is still conflicted, and which technical decisions most strongly shape survival, remodeling, and long-term failure.

This review shows that TCAR is not just another carotid stenting technique, but a potentially safer endovascular strategy with a recurrent signal for lower stroke and death risk than transfemoral CAS, especially when neuroprotection matters most. The full read is worth it because it clarifies where that advantage looks strongest, where the evidence is still mixed, and which anatomical, symptomatic, and restenotic subgroups may truly benefit from TCAR.

This paper shows that statins remain one of the strongest cardiovascular therapies, consistently linked to fewer major events and lower mortality across very large populations, but not without trade-offs such as diabetes risk, muscle symptoms, and rises in lipoprotein(a). The full paper is worth reading because it shows where the benefit is most convincing, where the risks matter most, and how to think more clearly about the real balance between protection and harm.

Semaglutide is not just a weight-loss drug — this review maps how it reaches across obesity, diabetes, cardiovascular disease, kidney protection, liver disease, and emerging neurologic pathways, while separating strong evidence from hype. The full paper is worth reading because it shows where semaglutide truly delivers the biggest clinical gains, where the safety and durability limits begin, and which future uses may matter most.

This review shows that rare vascular diseases are not just isolated curiosities: many are driven by shared pathways of vascular fragility, abnormal remodeling, and delayed diagnosis. It highlights where genetics, imaging, and targeted therapies are already turning rare vascular biology into practical clinical decisions.

Rural Australians have more heart disease and worse outcomes than people in metropolitan areas. Better prevention, telehealth, and regional cardiac care may help reduce this gap, but the available evidence is still insufficient.

WIfI combines true biological risk signals such as ischemia with limb-level consequences such as wound burden and infection to answer the central clinical question in PAD: is limb salvage still realistically achievable? This evidence map shows how WIfI stage translates into real-world amputation risk across clinical scenarios, and where its predictive value becomes strongest in modern decision-making.